A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
Humans
Lung Neoplasms
Piperazines
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Pyridines

authors with profiles

Richard Schilsky